SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player

SomaLogic is being acquired by Standard BioTools in an all-stock merger that creates a larger life-science tools group. The deal has closed after shareholder approval, putting the focus on integration, cost synergies and the combined group’s position in proteomics and genomics tools.

SomaLogic stock has entered a new phase after the company completed its previously announced all-stock merger with Standard BioTools, creating a combined life-science tools group focused on proteomics and genomics platforms, according to a closing announcement published on 01/05/2024 by Standard BioTools and SomaLogic on their investor relations pages and reported by Reuters as of 10/04/2023.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SomaLogic Inc
• Sector/industry: Life-science tools, proteomics
• Headquarters/country: Boulder, Colorado, USA
• Core markets: Proteomics research, biopharma, clinical research labs
• Key revenue drivers: Proteomic assay services, technology licensing, platform placements
• Home exchange/listing venue: Nasdaq (prior to merger, ticker SLGC)
• Trading currency: US dollar (USD)

SomaLogic: core business model

SomaLogic built its business around large-scale proteomics, offering tools that measure thousands of proteins in a single sample using proprietary SOMAmer reagents and related assay technologies. The company’s core model combined fee-for-service proteomics analysis for research customers with a longer-term strategy of deploying its platforms directly into laboratories and healthcare institutions, according to SomaLogic’s description of its business in its 2023 filings summarized by SEC filings as of 03/15/2024.

The company positioned itself at the intersection of life-science tools and data-driven healthcare, aiming to turn protein measurements into clinically relevant insights for drug discovery, early disease detection and precision medicine. Its proteomics platform was marketed to pharmaceutical companies, academic researchers and, in some cases, diagnostic developers, with the idea that broad, high-throughput protein data can reveal disease signatures and treatment response patterns that are not accessible through genomics alone, as highlighted in SomaLogic’s corporate materials referenced in SomaLogic investor updates as of 03/28/2024.

Revenue historically came mainly from research-use-only services and collaborations rather than from fully approved diagnostic products. This structure meant that SomaLogic’s financial performance was linked to R&D budgets in biopharma and academia, as well as to longer-term efforts to embed its technology in routine clinical workflows. The company also emphasized the value of its large proteomics database, built from many thousands of human samples, as a potential asset for partners seeking biomarker discovery and patient stratification tools.

Main revenue and product drivers for SomaLogic

Before the merger, SomaLogic’s main revenue driver was its proteomics assay service, in which customer samples were sent to SomaLogic-operated laboratories for analysis using its high-plex SOMAscan assay. Customers received quantitative data on thousands of proteins per sample as well as bioinformatics support, and these services accounted for the majority of 2023 revenue, according to the company’s full-year 2023 report summarized in SomaLogic investor updates as of 03/28/2024.

The firm also generated income from strategic collaborations and licensing agreements, where partners could access the platform and data for specific therapeutic or diagnostic programs. These arrangements sometimes included milestone or development payments, making that revenue stream less predictable but potentially higher margin when successful. In addition, SomaLogic sought to expand instrument placements and kits through relationships with established lab-equipment players, aiming to broaden adoption beyond centralized service labs.

Growth expectations centered on increasing sample throughput, broadening the installed base of platforms, and deepening relationships with large biopharma customers that run multi-year biomarker programs. At the same time, the company’s cost structure reflected substantial R&D investment and sales and marketing spending, as it attempted to educate the market on high-plex proteomics and differentiate its approach from competing platforms such as mass spectrometry or antibody-based arrays, a competitive landscape frequently discussed in sector commentary compiled by mainstream life-science tools coverage on portals such as Reuters as of 10/04/2023.

Industry trends and competitive position

The merger with Standard BioTools places SomaLogic within a broader life-science tools platform at a time when proteomics is gaining attention as a complement to genomics in drug development and biomarker research. Analysts and industry observers have noted that large pharmaceutical companies increasingly seek multi-omics data, combining genome, transcriptome and proteome information to understand disease mechanisms, according to sector overviews on proteomics trends reported by Bloomberg as of 09/19/2023.

Within this context, SomaLogic’s technology competes with other high-throughput proteomics platforms that use nanopore-based sensing, proximity extension assays or advanced mass spectrometry. The company’s differentiation has historically been based on the scale of its protein panels, the reproducibility of measurements and the accumulated database of clinical samples. By combining with Standard BioTools, which brings microfluidics-based genomics and single-cell tools, the new group aims to be a more diversified supplier, potentially smoothing revenue volatility tied to any single modality, as referenced in the merger presentation circulated on 10/04/2023 and summarized by Standard BioTools investor communications as of 10/04/2023.

Competition remains intense, with multiple public and private companies targeting the same customer budgets for translational research and clinical biomarker programs. Pricing, platform performance, ease of use and data-analysis capabilities all influence customer choices. In addition, some pharma clients still rely heavily on lower-plex, targeted assays for specific proteins, which can delay broad adoption of high-plex approaches. These dynamics mean that even as the combined Standard BioTools–SomaLogic entity gains scale, it must continue to invest in technology development and commercial execution to maintain or improve its competitive position.

Why SomaLogic matters for US investors

For US investors, SomaLogic has been part of a broader group of emerging life-science tools companies seeking to monetize next-generation research technologies through a mix of services and instrument sales. The company’s listing on Nasdaq under the ticker SLGC before completion of the merger reflected its status as a high-growth, high-uncertainty player in the proteomics niche, exposed to fluctuations in biotech funding cycles and R&D spending. These characteristics can make such stocks more volatile than larger, diversified life-science tools peers.

The merger consideration for SomaLogic shareholders consisted of shares in Standard BioTools, effectively shifting investors’ exposure from a pure-play proteomics story to a more diversified platform that includes genomics and single-cell analysis. The terms of the transaction, including the all-stock exchange ratio and expected cost synergies, were laid out in the joint press release and proxy materials filed in late 2023 and early 2024, and the closing was confirmed in early January 2024, as described by Standard BioTools and SomaLogic investor announcements as of 01/05/2024.

At a portfolio level, the combined company is still firmly linked to US and global biotech capital markets. Changes in interest rates, risk appetite for unprofitable growth companies and funding flows into pharma R&D can all influence sentiment. For US-based retail investors, this means that developments at the merged entity are often interpreted in the wider context of the health-care innovation cycle, with periods of enthusiasm followed by risk-off phases. Past trading in SomaLogic shares has shown that earnings updates, guidance changes and major contract announcements can trigger pronounced share-price moves in relatively short time frames.

Conclusion

The completion of the all-stock merger between SomaLogic and Standard BioTools marks a strategic turning point for the former Nasdaq-listed proteomics specialist. SomaLogic has contributed a high-plex proteomics platform, extensive protein data assets and a roster of research-focused customers, while Standard BioTools adds complementary genomics and single-cell tools and a broader commercial infrastructure. Together, the combined company aims to gain scale, reduce costs and position itself as a multi-omics tools provider, though execution risks around integration, technology roadmaps and market adoption remain. For US investors who previously held SomaLogic shares, the investment case now depends less on SomaLogic as a stand-alone entity and more on how effectively the merged group can convert its scientific capabilities into sustainable revenue growth and improved profitability over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.